Aigen Investment Management LP Acquires New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Aigen Investment Management LP purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 5,948 shares of the company's stock, valued at approximately $685,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of NBIX. GSA Capital Partners LLP raised its stake in shares of Neurocrine Biosciences by 441.3% during the 3rd quarter. GSA Capital Partners LLP now owns 8,682 shares of the company's stock worth $1,000,000 after buying an additional 7,078 shares in the last quarter. Los Angeles Capital Management LLC grew its holdings in shares of Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock worth $48,479,000 after acquiring an additional 363,863 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Neurocrine Biosciences by 16.5% during the third quarter. Crossmark Global Holdings Inc. now owns 8,487 shares of the company's stock worth $978,000 after purchasing an additional 1,204 shares during the last quarter. Sigma Planning Corp purchased a new stake in Neurocrine Biosciences during the third quarter worth $230,000. Finally, Covestor Ltd grew its holdings in Neurocrine Biosciences by 11.5% in the third quarter. Covestor Ltd now owns 1,779 shares of the company's stock valued at $205,000 after purchasing an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Performance

Shares of NASDAQ NBIX traded down $2.41 during midday trading on Thursday, reaching $123.10. The stock had a trading volume of 475,002 shares, compared to its average volume of 863,620. Neurocrine Biosciences, Inc. has a twelve month low of $107.84 and a twelve month high of $157.98. The company's 50 day moving average price is $118.53 and its 200 day moving average price is $132.88. The firm has a market cap of $12.46 billion, a price-to-earnings ratio of 33.35 and a beta of 0.35.

Analyst Ratings Changes

NBIX has been the topic of several analyst reports. Citigroup raised their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the stock a "neutral" rating in a report on Friday, August 2nd. BMO Capital Markets cut their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a report on Thursday, October 17th. JPMorgan Chase & Co. increased their price objective on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the company an "overweight" rating in a report on Wednesday, August 7th. StockNews.com downgraded shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Friday, November 1st. Finally, Robert W. Baird upped their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.